18 May 2013
Keywords: Astellas, Medivation, Licensing, Prostate cancer, MDV3100
Article | 27 October 2009
In yet another mega-dollar drug licensing deal, Japanese major Astellas Pharma has entered into a global agreement to develop and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 October 2009
28 October 2009
17 May 2013
© 2013 thepharmaletter.com